INTRODUCTION
Angiosarcoma is a malignant neoplasm of endothelial cells that begins in the lining of the blood vessel wall.
Although angiosarcoma of the breast is a rare entity, the breast is a favorable site for it [1] . Breast angiosarcomas may be categorized as primary or secondary angiosarcoma.
Primary angiosarcoma arises within the breast parenchyma, the overlying skin, and subcutaneous tissue. In contrast, secondary angiosarcoma of the breast is commonly associated with radiation therapy in patients who have undergone breast-conserving surgery for another type of primary neoplasm of the breast. These secondary angiosarcomas occur several years after the initial treatment, are often associated with lymphedema, and involve the skin. Primary angiosarcomas account for fewer than 0.04% of all malignant breast neoplasms, and tend to occur in younger patients with no prior history of malignancy [1, 2] .
The prognosis is poor for patients with primary angiosarcomas as compared with invasive ductal carcinomas.
Angiosarcomas are highly aggressive vascular and soft tissue malignancies. Angiogenesis, believed to be strongly influenced by vascular endothelial growth factor (VEGF), is crucial in the pathogenesis of these tumors. The histo-thesurgery.or.kr logic grade of primary angiosarcoma of the breast plays an important role in the prediction of outcomes [3, 4] . Because high-grade primary breast sarcomas behave like extremity sarcomas, some authors have advocated using the same treatment protocol: surgical resection followed by adjuvant chemotherapy and radiotherapy [5] . Because of its rarity, the clinical course of primary breast angiosarcoma remains unclear, although metastases involving lung, liver, and other organs have been reported.
Here we present the clinical course of a 47-year-old female with primary angiosarcoma of the breast which showed recurrence to the chest wall and fatal lung complication with the review of literature. The tumor was positive for VEGFR-2 and CD-34 (Fig. 2C) .
CASE REPORT
The patient was treated with adjuvant chemotherapy of Following this, the patient underwent radiation therapy on the left chest wall with 50 Gy for 5.5 weeks. CT, and bone scan were normal. A biopsy was done in the left axilla. Histological diagnosis was lymphangioendothelioma, which was benign. We decided on follow-up 6 months later due to the possibility of local recurrence.
In January 2011, the patient returned complaining of thesurgery.or.kr dyspnea that had started 1 week prior. A chest X-ray showed a large pleural effusion in the left side (Fig. 3A) . The clinical course for this patient was very difficult due to the recurrence of tumor and complicated by an intractable thrombocytopenia. There are two hypotheses that may explain this thrombocytopenia. The first is that it was due to antiplatelet antibody. The second is that it may have resulted from antitumoral consumption of platelets. This platelet consumption may have been due to defective synthesis of prostaglandin I2 by neovascular endothelium or to the release of a platelet aggregating substance by tumor cells [7] . Endothelial cells express several kinds of cell adhesion molecules, including ICAM-1, VCAM-1, and PECAM-1 [8] , but in this case, we were not able to evaluate for these molecules. Such an evaluation may have been useful to confirm that the patient's thrombocytopenia was due to the angiosarcoma.
Uncontrolled Thrombocytopenia in this case is similar with the consumptive coagulopathy seen in KasabachMeritt syndrome, which is characterized by platelet sequestration and consumption of clotting factors within the vascular bed of giant angiomatous naevi [9] . The widespread skin lesion, which was diagnosed as angiosarcoma had been observed in the left chest wall. So, we deemed that the uncontrolled thrombocytopenia was caused by persistent platelet consumption in the large skin lesion.
In high-grade angiosarcoma, the current treatment mo- [4] . In this case, the patient had a grade 3 tumor and the time to disease recurrence was about 18 months.
Metastases occur most frequently to the lung, bone, liver, and chest wall [1] . Although not confirmed by biopsy, this patient had evidence of metastasis to the lung. She developed dyspnea, hemoptysis, and episodes of pleural hemorrhage beginning about 18 months after initial treatment and persisting until death. The hemoptysis is considered to have been caused by alveolar hemorrhage secondary to the suspected pulmonary metastasis, rather than spontaneous bleeding secondary to the thrombocytopenia. We suggest the patient died due to uncontrolled bleeding stemming from the alveolar hemorrhage.
Because primary angiosarcoma of the breast is so aggressive and rare, there is currently no consensus data for standard treatment or clinical course. We have detailed our experience with a primary breast angiosarcoma that failed to respond to multimodality treatment of surgical resection and adjuvant chemotherapy and radiotherapy.
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